BIIB vs NBIX
BIIB: A pioneer in neuroscience and immunology, Biogen is a major biotechnology company focused on addressing high-unmet medical needs in complex diseases like Alzheimer’s, Multiple Sclerosis, and SMA. NBIX: Neurocrine is a profitably growing, neuroscience-focused biotech commercializing novel treatments for movement disorders, endocrine diseases, and psychiatric conditions with expanding late-stage pipeline and recent M&A.
Side-by-side fundamentals
| Metric | BIIB | NBIX | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $200.14 | $176.41 | |
| Market cap as of 2026-07-30 | $31.8B | $17.7B | |
| P/E as of 2026-07-30 | 23.19 | 27.35 | BIIB lower |
| PEG as of 2026-07-30 | 10.24 | 0.23 | NBIX lower |
| Net margin as of 2026-07-30 | +13.8% | +21.6% | NBIX higher |
| Gross margin as of 2026-07-30 | +75.5% | +98.2% | NBIX higher |
| Operating margin as of 2026-07-30 | +17.5% | +25.4% | NBIX higher |
| ROE as of 2026-07-30 | +7.5% | +21.6% | NBIX higher |
| ROA as of 2026-07-30 | +4.7% | +15.1% | NBIX higher |
| Debt / equity as of 2026-07-30 | 0.34 | 0.00 | NBIX lower |
| Revenue growth (YoY) as of 2026-07-30 | +1.2% | +28.6% | NBIX higher |
| Revenue CAGR (3y) SEC XBRL | -0.9% | +24.3% | NBIX higher |
| Beta as of 2026-07-30 | 0.16 | 0.37 | |
| 1-year return as of 2026-07-27 close | +52.2% | +33.5% | BIIB higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.